Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs YPF Sociedad Anonima American Depositary Shares — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while YPF Sociedad Anonima American Depositary Shares trades at $52.38 (market cap $20.31B). The key difference: YPF Sociedad Anonima American Depositary Shares is far larger — about 20.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and YPF Sociedad Anonima American Depositary Shares is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and YPF Sociedad Anonima American Depositary Shares for 6 Days on average.
| MRVI | YPF | |
|---|---|---|
Market Cap | $972.90M | $20.31B |
Volume | 4,325,710 | 1,015,599 |
Sector | Health | Energy |
52-Week High | $9.00 | $57.61 |
52-Week Low | $2.83 | $24.71 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $28.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
YPF trades at $51.79, down 0.35% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating estimates and strong revenue growth from $18.3B in 2025 to $20.6B projected for 2026. Recent developments include a $24B LNG project gaining U.S. financing support and record quarterly cash flow generation.
The outlook remains positive with analyst consensus at Buy (46.7%) and a $56.67 price target representing 9.4% upside. Key risks include political uncertainty in Argentina and execution challenges for major capital projects. The stock offers value with attractive EV/EBITDA of 3.91x but faces margin pressure from high tax burdens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
